Cardiovascular Risk Associated With Acarbose Versus Metformin as the First-Line Treatment in Patients With Type 2 Diabetes: A Nationwide Cohort Study | Zendy

ChiaHsuin Chang | Zendy; YiCheng Chang | Zendy; JouWei Lin | Zendy; ShuTing Chen | Zendy; LeeMing Chuang | Zendy; MeiShu Lai | Zendy

Open Access

Cardiovascular Risk Associated With Acarbose Versus Metformin as the First-Line Treatment in Patients With Type 2 Diabetes: A Nationwide Cohort Study

Author(s) -

ChiaHsuin Chang,

YiCheng Chang,

JouWei Lin,

ShuTing Chen,

LeeMing Chuang,

MeiShu Lai

Publication year - 2015

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2014-2443

Subject(s) - acarbose , medicine , metformin , hazard ratio , myocardial infarction , type 2 diabetes , diabetes mellitus , stroke (engine) , cohort , cohort study , propensity score matching , confidence interval , heart failure , proportional hazards model , endocrinology , insulin , mechanical engineering , engineering

Metformin is the first-line oral therapy for type 2 diabetes with proven benefits against cardiovascular risk. Recent evidence suggested that acarbose might be similar to metformin in glucose-lowering efficacy and cardiovascular risk reduction. Therefore, international guidelines have suggested the use of acarbose as alternative first-line antidiabetic therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research